Baxter International (NYSE:BAX) Issues FY 2025 Earnings Guidance

Baxter International (NYSE:BAX) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 2.450-2.550 for the period, compared to the consensus estimate of 2.460. The company issued revenue guidance of $11.2 billion-$11.3 billion, compared to the consensus revenue estimate of $11.2 billion. Baxter International also updated its Q1 2025 guidance to 0.470-0.500 EPS.

Baxter International Price Performance

BAX opened at $30.86 on Thursday. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31. The business has a fifty day moving average of $30.52 and a 200 day moving average of $34.15. Baxter International has a 52-week low of $28.33 and a 52-week high of $44.01. The stock has a market cap of $15.75 billion, a P/E ratio of 154.28, a PEG ratio of 9.83 and a beta of 0.61.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.06. Baxter International had a net margin of 0.77% and a return on equity of 18.30%. As a group, sell-side analysts anticipate that Baxter International will post 1.83 EPS for the current year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 2.20%. The ex-dividend date of this dividend is Friday, February 28th. Baxter International’s dividend payout ratio is presently 340.02%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Citigroup reduced their price objective on Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. StockNews.com downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. Finally, Stifel Nicolaus dropped their target price on shares of Baxter International from $46.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $39.44.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.